Mirum Pharmaceuticals Inc
$ 107.48
1.50%
24 Feb - close price
- Market Cap 6,340,689,000 USD
- Current Price $ 107.48
- High / Low $ 109.28 / 105.28
- Stock P/E N/A
- Book Value 5.69
- EPS -0.84
- Next Earning Report 2026-02-25
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.04 %
- ROE -0.16 %
- 52 Week High 109.28
- 52 Week Low 36.88
About
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of an advanced line of novel therapies for debilitating liver diseases. The company is headquartered in Foster City, California.
Analyst Target Price
$116.09
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-25 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.02 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MIRM
2026-02-23 21:00:47
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) announced its participation in several upcoming investor conferences in March 2026. The company will hold fireside chats at TD Cowen's 46th Annual Health Care, The Citizens Life Sciences, and Leerink Partners Global Healthcare Conferences, and will also attend Barclays 28th Annual Global Healthcare Conference. Webcasts of the fireside chats will be available on Mirum's corporate website.
2026-02-20 21:17:10
This article focuses on the treatment of pruritus using Maralixibat. The case study involves a child diagnosed with Alagille Syndrome who is experiencing early-stage chronic graft dysfunction. The content provided appears to be a journal's navigation and registration interface rather than the full article.
2026-02-19 14:50:58
Mirum Pharmaceuticals will report its fourth quarter and year-end 2025 financial results on February 25, 2026, and will host a conference call to discuss these results and recent corporate progress. The call is scheduled for 4:30 p.m. ET / 1:30 p.m. PT. Mirum Pharmaceuticals is a rare disease company with approved products like LIVMARLI®, CHOLBAM®, and CTEXLI®, and a pipeline of investigational medicines.
2026-02-19 12:57:41
Royal Bank Of Canada upgraded Mirum Pharmaceuticals (NASDAQ:MIRM) to a "moderate buy" rating. Other firms like Evercore, Leerink Partners, HC Wainwright, Citigroup, and Wall Street Zen have also issued positive ratings, with a consensus price target of $110.17. The article also details recent insider stock sales by SVP Jolanda Howe and CFO Eric Bjerkholt, and mentions institutional investor activity.
2026-02-19 09:57:11
Mirum Pharmaceuticals (MIRM) has experienced significant share price momentum, driven by its focus on rare and orphan liver diseases and an expanding commercial portfolio. While the stock is currently seen as undervalued with a fair value estimate of $106.60 against a recent price of $105.10, the company faces execution risks related to its key therapy, Livmarli, and upcoming late-stage PSC data. Investors are encouraged to review the company's financial details and risk factors to form an independent view.
2026-02-19 00:57:41
Mirum Pharmaceuticals (NASDAQ:MIRM) stock reached an all-time high of $106.27, surpassing its 52-week high, following an impressive 101.38% increase over the past year. The company's strong performance is attributed to investor confidence, positive product pipeline developments, revenue growth, and significant acquisitions like Bluejay Therapeutics. Analysts remain bullish, with high price targets, reflecting optimism about Mirum's future prospects in the rare liver disease market.
